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The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon
not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally
similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs,
the response to type III IFN is highly cell-type speciﬁc. Only epithelial-like cells and to a lesser extent some immune cells respond
to IFN-λ. This particular pattern of response is controlled by the diﬀerential expression of the IFN-λ receptor, which, in contrast
to IFN-α, should result in limited side eﬀects in patients. Recently, we and other groups have shown in several animal models a
potent antitumor role of IFN-λ that will open a new challenging era for the current IFN therapy.
1.Introduction
Despite the early discovery of interferon (IFN) in 1957, IFN
lambdas were just identiﬁed during the recent years and
classiﬁed as a new group, type III IFN. In human, 3 distinct
proteins called IFN-λ1, IFN-λ2, and IFN-λ3h a v eb e e n
identiﬁed [1, 2]. They are also named interleukin-29 (IL-
29), IL-28A, and IL-28B, respectively [3]. The members of
this new IFN family were found to interact through unique
receptors that are distinct from type I (IFN-α/β)a n dt y p e
II (IFN-γ) IFN receptors. The receptor for type III IFN
is composed of the unique IFN-λR1 chain also called IL-
28AR and the IL-10R2 chain, which is shared with IL-10,
IL-22, and IL-26 receptor complexes. Although type III IFNs
bind to a speciﬁc receptor, the downstream signaling is
similar to that induced by type I IFNs. Both type I and type
III IFNs stimulate common signaling pathways, consisting
of the activation of Jak1 and Tyk2 kinases and leading
to the activation of IFN-stimulated gene factor 3 (ISGF3)
transcription complex. ISGF3 is composed of STAT1 and
STAT2 and the interferon regulatory factor IRF9 (ISGF3-γ
or p48) (Figure 1). Although there are three genes encoding
highlyhomologousbutdistincthumanIFN-λproteins(IFN-
λ1, IFN-λ2, and IFN-λ3), our search of the mouse genome
revealed the existence of only two genes, representing mouse
IFN-λ2 and IFN-λ3 gene orthologues, located in chromo-
some 7 and encoding intact proteins. The mouse IFN-λ1
gene orthologue is a pseudogene containing some variations
inadditiontoastopcodonintheﬁrstexonanddoesnotcode
for an active protein [4]. We have cloned the mouse IFN-
λs (mIFN-λ2 and mIFN-λ3) and IFN-λ receptor (mIFN-
λR1) orthologues and found them to be quite similar to
their human counterparts. Experiments showed that similar
to their human counterparts, mIFN-λ2 and mIFN-λ3 signal
through the IFN-λ receptor complex, activate ISGF3, and are
capable of inducing antiviral protection and MHC class I
antigen expression in several cell types. The results showed
that murine type III IFNs (IFN-λs) engage a unique receptor
complex, composed of IFN-λR1 and IL-10R2 subunits, to
induce signaling and biological activities similar to those of
type I IFNs. Interestingly, in contrast to type I and type II
IFNs, type III IFNs demonstrate less species speciﬁcity.
2. Biological Propertiesof IFN-λ
2.1. Restrictive Cell Response to Type III IFN (IFN-λs).
Although type I and type III induced similar cell signaling,2 Clinical and Developmental Immunology
ISRE
IFN-α system IFN-λ system
IFNAR1 IFNAR2 IFN-λR1 IL-10R2
Jak1 Tyk2 Jak1 Tyk2
Stat1
Stat2 p48
ISGF3
Nucleus
Cytoplasm
Figure 1: IFN-α and IFN-λ receptor systems and cell signaling. IFN-α and IFN-λ interact with distinct receptors, but the downstream
signaling is similar. IFN-α interacts with receptors composed of IFNAR1 and IFNAR2, and IFN-λ interacts with a receptor composed of a
speciﬁc chain, IFN-λR1, and IL-10R2, a shared subunit with IL-10, IL-22, and IL-26. Both IFNs lead to the activation of the Jak kinases (Jak1
and Tyk2) and the formation of the transcription-complex-designated IFN-stimulated gene factor 3 (ISGF3), which includes p48, Stat1, and
Stat2. ISGF3 complex binds to the IFN-stimulated response element (ISRE) and induces gene transcription.
the intensity of cell signaling as measured by STAT1 acti-
vation appeared to be signiﬁcantly lower for type III IFNs
[4]. In comparison with type I IFN, only restricted cell types
respond to type III IFN (Figure 2). Interestingly, we did not
ﬁnd a strict correlation between the intensity of cell signaling
induced by IFN-λ and the level of biological activity. For
example, in B16 melanoma cells, although IFN-λ induced a
v e r yw e a kS T A T 1a c t i v a t i o ni nc o m p a r i s o nw i t hI F N - α,w e
observed a robust stimulation of MHC class I expression at
the cell surface, indicating the potential contribution of cell-
speciﬁc modulators of the IFN-λ activity.
Antiviral studies performed in vitro and in vivo have
shown that both IFN-α and IFN-λ contribute to the overall
host antiviral defense system [2, 3, 5–8]. It has been demon-
strated that IFN-λ induces antiviral activity against VSV
(vesicular stomatitis virus) and EMCV (encephalomyocardi-
tis) in many human cell lines [2, 3, 9, 10]. However, by
using diﬀerent mouse models of viral infection, Ank et al.
demonstrated that IFN-λ was eﬀective against DNA virus,
simplex virus 2 HSV2 but not RNA viruses such as EMCV
and lymphocytic choriomeningitis virus LCMV [6]. Several
otherstudiesdemonstratedthattypeIIIIFNscanalsoinhibit
replication of hepatitis C virus (HCV) and hepatitis B virus
(HBV) in vitro [10–14]. These studies were important since
they underlined the fact that IFN-λ could be used as an
alternative to IFN-α for HCV patients who are resistant
to IFN-α treatment. It has been reported that IFN-λ has
the ability to inhibit human immunodeﬁciency virus type 1
(HIV-1) infection of blood monocyte-derived macrophages
that expressed IFN-λ receptors [15] and the herpes simplex
virus type 1 (HSV1) infection of human astrocytes and
neurons [16]. However, in most other cases, the antiviral
potency of IFN-λ against several viruses seems to be lower
than that of IFN-α [2, 3, 8, 9, 13, 17]. In addition, IFN-λ
and IFN-α may induce distinct signal transduction and gene
regulation kinetics [13, 18].
Moreover, type I IFN-α activates a plethora of innate and
adaptive immune mechanisms that help eliminate tumors
and viral infections. IFN-α immunoregulatory functions in-
clude major histocompatibility complex (MHC) class I ex-
pression in normal and tumor cells, activation of NK
cells, dendritic cells (DCs), and macrophages, resulting in
thepromotionofadaptiveimmuneresponsesagainsttumors
and virally infected cells [19, 20] .T h er o l eo fI F N - λ
in the immune system is currently being investigated by
several groups. So far, data suggests that IFN-λ exerts
immunomodulatory eﬀects that overlap those of type I
IFN. It has been recently demonstrated that human IFN-λ1
(IL-29) modulates the human plasmacytoid DCs function
and cytokine response [21, 22]. IFN-λ1t r e a t m e n to fw h o l e
peripheral blood mononuclear cells (PBMCs) upregulated
the expression of IL-6, IL-8, and IL-10 but not IL-1 or
TNF. This IFN-λ-induced cytokine production was inhibited
by IL-10. By examination of puriﬁed cell populations, it
was also shown that IFN-λ1 activated monocytes, rather
than lymphocytes, resulting in the secretion of the above
panel of cytokines, suggesting that IFN-λ1m a yb ea n
important activator of innate immune responses particularly
at the site of viral infections [21]. IFN-λ1 was also shown
to possess immunoregulatory functions on T helper 2
(Th2) responses by markedly inhibiting IL-13. However,
only moderate eﬀect was observed on IL-4 and IL-15, theClinical and Developmental Immunology 3
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Figure 2: Cellular targets for type I and type III IFNs. Response to IFN-α and IFN-λ in cells from diﬀerent origins in human. The IFN
response was assessed by measuring the IFN-induced cell signaling (Stat activation) and cell activity (MHC class I antigen stimulation). In
contrast to IFN-α,o n l yr e s t r i c t e dc e l l sr e s p o n dt oI F N - λ, including epithelial-like cells, forming the major organs of the body.
other important cytokines in the Th2 response [23–25].
This immunoregulatory function was enhanced through the
expression of IFN-λR1 on CD4+ T cells [23]. These ﬁndings
correlate with data suggesting that IFN-λ may have an
immunoprotective role against asthma, the allergy disease
caused by an exaggerated Th2 response [9, 26, 27].
Similar to IFN-α,I F N - λ produced by DCs, in response
to toll-like receptor (TLR) stimulation, was found to have
speciﬁc eﬀects on DC diﬀerentiation and maturation [28],
which include only partial maturation of DCs, upregulation
of MHC class I and II molecules, and no induction of co-
stimulatory molecules [9, 29]. During their diﬀerentiation
from monocytes, DCs acquire IFN-λ responsiveness through
the expression of IFN-λR1. Interestingly, DCs treated
with IFN-λ promoted the generation of tolerogenic DCs
and the IL-2-dependent proliferation of Foxp3-expressing
CD4+CD25+ regulatory T cells (Tregs) [29]. More recently,
Morrow et al. have demonstrated, through DNA vaccination
with plasmids encoding IFN-λ3 (IL-28B) and IL-12, that
IFN-λ3,justlikeIL-12,isabletoenhanceadaptiveimmunity.
However, in contrast to IL-12, IFN-λ3 reduces regulatory T-
cell populations. They also showed that unlike IL-12, IFN-λ3
is able to increase the percentage of splenic CD8+ Tc e l l si n
vaccinated animals and that IFN-λ3 can completely protect
mice from death following a lethal inﬂuenza challenge [30].
These studies altogether highlight the strong candidacy of
IFN-λ as a potential novel immunotherapeutic agent.
In addition to antiviral and immunomodulatory activ-
ities, type I IFNs demonstrate antiproliferative activities in
most cell lines, while this activity seems to be restricted with
IFN-λs[ 9, 17]. Type I IFNs have been shown to induce
apoptosis in tumor cells, yet the molecular mechanisms
mediating cell death in response to these IFNs remain
to be fully explained. By binding to their corresponding
cellular receptor complexes, IFNs induce a quick and potent
signaling which leads to the expression of more than 300
IFN-stimulated genes (ISGs) [13, 31, 32]. Many ISGs encode
proteins that have been implicated in apoptosis [33, 34].
Unlike IFN-α,I F N - λs do not inhibit the proliferation of sev-
eral cell lines including the Daudi cells (a B-lymphoblastoid
cell line from Burkitt’s lymphoma), which strongly respond
to type I IFNs in an antiproliferative assay [2, 3, 10, 17].
However, it was demonstrated that IFN-λs do inhibit the
proliferation of few tumor cell lines, such as the LN319
human gliobastoma cell line [17] and of cells constitutively
expressing high levels of IFN-λR1 [35]. The antiproliferative
eﬀects of IFN-λ have been demonstrated in various tumor
cell lines that express ectopic or endogenous IFN-λ receptors
[17, 36, 37]. Therefore, the ability of IFN-λs to induce
antiproliferative activity in cells depends on the level of IFN-
λR1 expression.4 Clinical and Developmental Immunology
It has been recently reported that IFN-λ signaling in
colorectal adenocarcinoma HT29 cells led to caspase activa-
tion, externalization of phosphatidylserine (PS), and DNA
fragmentation, resulting in subsequent apoptosis [38]. This
study provided evidence for the ﬁrst time that type III
IFNs, alone or in combination with other stimuli, have
the potential to induce apoptosis. Moreover, another recent
study revealed that IFN-α and IFN-λ diﬀer in their antipro-
liferative eﬀects and this was correlated with a diﬀerence in
the duration of JAK/STAT signaling activity between the two
IFNs and prolonged ISG expression upon IFN-λ treatment
[18]. Using the human keratinocyte HaCaT cell line that
expresses receptors for both IFN-α and IFN-λ, they found
that IFN-λ induced a more pronounced growth inhibitory
eﬀect than IFN-α.I F N - λ was also more eﬃcient than IFN-α
in inducing an antiproliferative eﬀect that overlapped with
the activation of apoptosis. Prolonged duration of IFN-λ-
induced STAT activation, and ISG expression could account
for the enhanced antiproliferative and proapoptotic eﬀects
observed in HaCaT cells, eﬀects not seen upon treatment
with high doses of IFN-α [18]. Interestingly, a study has
shownthatIFN-λcaninducethegrowthofhumanmultiple-
myeloma cells and antagonize the dexamethasone-induced
cell death in these cells [39]. IFN-λ-mediated cell growth of
multiple myeloma cells was MAPK dependent [39]. High
level of IFN-λ was found in the malignant bone marrow
microenvironment, implying that IFN-λ m a yp l a yad i r e c t
role in multiple myeloma development.
2.2. Tissue and Species Speciﬁcity of Type III IFN (IFN-λ).
By using a plasmid electrotransfer approach, Sommereyns
and coworkers reported a diﬀerential response to IFN-λ in
mice, with a very low response to IFN-λ for the liver, central
nervous system, and spleen. However, a high response to
IFN-λ was observed in the stomach, intestine, heart, kidney,
andlung[40].TheIFN-λresponsewasrestrictedtoepithelial
cells and correlated with the expression of IFN-λR( I L -
28Ralpha). Paradoxically in mice, in spite of the epithelial
nature of the hepatocytes, the liver expressed low levels
of IL-28Ralpha and responded poorly to IFN-λ [8, 40].
However, a signiﬁcant response to IFN-λ was reported in
human hepatocytes [13, 32], suggesting the existence of
some variations in the response to IFN-λ between mice
and humans, at least in the liver. Although the main IFN-λ
targetsaretheepithelialcells,thepresenceofpotentialtissue-
speciﬁc factors may modulate the IFN-λ response through
the IFN-λ receptors. Recently, it has been shown in mice that
in contrast to the hepatocytes, prominent response to IFN-
λ was observed in intestinal epithelial cells. In comparison
withIFN-α, this response is higher and plays a critical role in
protectingtheintestinalepitheliumfromviralinfection[41],
strongly suggesting the prominent role of IFN-λ in organs
with mucosal surface at least in mice [6, 42, 43]. In addition
to the direct eﬀect of IFN-λ on the mucosal epithelium, local
immunomodulations can also be promoted [44].
2.3. Distribution of IFN-λR1 and Responsiveness to IFN-λ.
The functional IFN-λR is formed by two chain proteins,
IFN-λR1 (also called IL-28Ralpha) and IL-10R2. IFN-λR1 is
unique for the IFN-λs, and its tissue distribution is highly
restricted. In contrast to IFN-λR1, IL-10R2 is shared by
IL-10, IL-22 and IL-26 and ubiquitously expressed in all
tissues. Unlike IFN-α, only few cell types respond to IFN-λ
(Figure 2). In contrast to the epithelial-like cells, ﬁbroblasts
and endothelial cells were completely unresponsive to IFN-λ
[4]. Although the hematopoeitic system is not the primary
target of IFN-λ, the response of some subpopulations to
IFN-λ is not excluded. In mice, we found that IFN-λ
induces STAT1 activation in both plasmacytoid and myeloid
dendritic cells [45]. These results are in accordance with
those obtained by Mennechet and Uz´ e[ 29], who proposed
theacquisitionofanIFN-λresponsebymonocytesaftertheir
diﬀerentiation into dendritic cells. Therefore, the response
to IFN-λ may be controlled by the induction of the IFN-
λR1 expression. Diﬀerent levels of IFN-λR1 were found
in diﬀerent tissues [40, 43, 46]. The highest levels were
found in the gastrointestinal tract and lung. The brain
showed the lowest level of receptor expression. The IFN-
λR1 expression was also analyzed in diﬀerent cell types.
The expression of cell populations isolated from human
skin showed a high expression of IFN-λR1 in keratinocytes
and melanocytes. However, dermal ﬁbroblasts, endothelial
cells, and subdermal adipocytes did not express signiﬁcant
amounts of IFN-λR1. Signiﬁcant expression of IFN-λR1 was
detected in primary human hepatocytes in comparison with
the chondrocytes, isolated from the hyaline cartilage of the
knee joint [46, 47]. Although the expression of IFN-λR1 was
signiﬁcantly high in lymphoid tissues, the IFN-λ response
was very weak, implying the presence of speciﬁc mechanisms
in the lymphoid tissues that may inhibit the IFN-λ response.
For example, IFN-λR1 levels in B cells are threefold those
detected in keratinocytes, which exhibit one of the highest
responses to IFN-λ. Witte et al. proposed the potential role
of soluble IFN-λR1, highly released by the immune cells, in
this weak response to IFN-λ [46].
Although all the IFN-λs interact with the same receptor,
IFN-λR1, the binding characteristics for each ligand are still
under investigation. In the future, it will be important to
analyze the IFN-λ activity in light of the IFN-λ binding
to the cells and understand particularly the role of IFN-
λ3, which possesses the highest activity as compared with
the other IFN-λs[ 48, 49]. Analysis of the ligand binding in
combination with the activity induced by IFN-λ will be also
importantinunderstandingtheimpactofIFN-λinepithelial
cells, particularly in comparison with the immune cells
expressing IFN-λR1. Besides several carcinomas, originating
from epithelial cells, which respond to IFN-λ, other tumors
not arising from epithelial cells may become more sensitive
to IFN-λ. It was reported that multiple myeloma cells, which
originate from B-cell plasmocytes, showed high binding and
response to IFN-λ [39]. Studying the IFN-λ binding in
transformed cells versus normal cells may be very helpful for
tumor targeting and for the establishment of the optimum
dose of IFN-λ to be used for the in vivo treatment. IFN-λ can
also be used as a drug carrier, to speciﬁcally target a drug to
tumors expressing high IFN-λ binding sites.Clinical and Developmental Immunology 5
2.4. Antiviral Protection in IFN-Type-III-Deﬁcient Mice. The
availability of IFN-λR1 knock-out mice allowed for the
investigation of the role of type III IFNs in vivo. By using
those mice, Mordstein et al. showed for the ﬁrst time the
contribution of IFN-λ in the innate immunity against the
inﬂuenza virus [8]. Later, they found that IFN-λ played an
important role in the defense against other pathogens that
infect the respiratory tract, such as the respiratory syncitial
virus,themetapneumovirus,andthesevereacuterespiratory
syndrome(SARS)coronavirus.However,thelassafevervirus
which replicates in the liver, was not aﬀected by the lack
of IFN-λR1 [50]. Although this study clearly demonstrated
that IFN-λ played an important role in protecting the
respiratory and gastrointestinal tracts against virus infection,
in comparison with type I IFN, the protection provided by
type III IFN remains limited. However, in combination, type
I and type III may provide a better viral protection. When
the response to both type I and type III is deﬁcient, the mice
are not able to clear the SARS coronavirus from the intestine
as compared with mice in which type I or type III remains
functional, implying that IFN-λ may strengthen the antiviral
activity by acting as a ﬁrst line of defense for the mucosa
[8, 50].
2.5. Clinical Use of Type III IFN. The ﬁrst use of IFN-λ in
the clinic has started for hepatitis C. The phase 1b study has
been conducted in patients with chronic genotype 1 hep-
atitis C virus infection ((HCV) [51]). Pegylated IFN-λ1i n
combination or not with ribavirin (RBV, which belongs
to a class of antiviral medications called the nucleoside
analogues) has been used in this study to assess the eﬃcacy
and the potential cytotoxicity. The study was performed
in 3 parts. The ﬁrst part evaluated the pegylated IFN-
λ as single agent for relapsed patients after IFN-α-based
treatment. The second part concerned the combination of
pegylated IFN-λ and RBV in treatment-relapse patients.
The third part evaluated pegylated IFN-λ in combination
with RBV in treatment-na¨ ıve patients. In addition, diﬀer-
ent doses (from 0.5 to 3microg/kg) of pegylated IFN-λ
were used. Fifty-six patients were enrolled. 24, 25, and 7
patients were used, respectively, for part 1 to 3. The data
showed an antiviral activity in all doses of pegylated IFN-
λ tested. 29% of treatment-na¨ ıve patients achieved rapid
antiviral response. As expected, due to the limited IFN-
λR1 distribution, the treatment was well tolerated with
few adverse eﬀects. Minimal ﬂu-like symptoms and limited
hematologic suppression were reported. In summary, the
authors concluded that weekly pegylated-IFN-λ with or
without daily RBV for 4 weeks is associated with a clear
antiviral activity in patients with chronic HCV. However,
this study lacks a direct comparison between IFN-λ and
IFN-α and the inﬂuence of viral and patient genotypes.
Now it is well accepted that the response to IFN-α or the
natural clearance of HCV infection is depending on single-
nucleotide polymorphisms (SNPs), upstream of IFN-λ3,
which could be used as biomarkers to help determine the
treatment outcome [52]. The ﬁrst genome-wide association
studies (GWAS) in HCV infection were reported by Ge et al.
They evaluated the treatment outcome in a group of 1671
patients of mixed ethnicity, receiving pegylated IFN-α and
ribavirin. An association was discovered between sustained
viral response (SVR) to treatment and a cluster of seven
SNPs linked to the IFN-λ3 gene, with the most signiﬁcant
SNP(rs12979860)demonstratinghighstatisticalsigniﬁcance
[53]. Many other studies have replicated these ﬁndings,
demonstrating the high link between IFN-λ3 and treatment
outcome [54–61]. However the mechanisms explaining this
link remain to be determined. It is not clear yet if this
SNP is associated with a constitutive production of IFN-λ
that may play a role in HCV clearance and the success of
IFN-α treatment. These results also suggest the therapeutic
potential of the IFN-α and IFN-λ combination therapy
as demonstrated for the hepatocellular carcinoma (HCC)
mouse model [62].
3. Emergence of IFN-λ as a New
Antitumor Agent
3.1. Characterization of the IFN-λ System and Demonstration
of Its Antitumor Activity in a Melanoma Model. Although
they engage distinct receptors, IFN-α and IFN-λ induce
similar cell signaling (Figure 1). Since IFN-α is widely used
in the clinic to treat cancer (Table 1), we have investigated
the potential antitumor activity of IFN-λ by using the mouse
B16 melanoma model. We have chosen this cancer model
because melanoma is a very aggressive cancer, and one of
the therapeutic agents frequently used in the treatment of
melanoma is IFN-α. Signiﬁcant improvements in relapse-
free and overall survival, with postoperative adjuvant IFN-
α therapy, have been reported by large and randomized
studies [63–65]. However, the beneﬁcial eﬀect of IFN-α
was only obtained when the patients received high doses
(20MIU/m2intravenously ﬁvetimes perweek).Studies with
low doses of IFN-α have not shown signiﬁcant increase
i no v e r a l ls u r v i v a l[ 66, 67]. Usually, the dose for optimal
antitumor activity is higher than the maximally tolerated
dose. This dose dilemma profoundly aﬀects the acceptance
of IFN-α treatment by both the clinicians and the patients.
The adverse eﬀects associated with high doses of IFN-α
include myelosuppression and nervous system disorders.
These eﬀects often compromise the beneﬁcial antitumor
eﬀect, with premature discontinuation of the treatment or
the reduction of the dose of IFN-α. Since virtually all the
cells of the body respond to IFN-α, it is not surprising
that the patients develop numerous side eﬀects. Making
a dissection between the beneﬁcial and harmful eﬀects of
IFN-α is a very challenging task, which requires more in-
vestigation of the interferon system. To investigate the
antitumor eﬀect of IFN-λ in melanoma, we have used a
gene therapy approach, consisting on the delivery of the
IFN-λ gene to tumor cells. Gene transfer into tumor cells
is very useful approach to test the eﬀectiveness of cytokines
in animal cancer models. This approach does not require
production and puriﬁcation of the protein. The secretion
of constant amounts of various cytokines by transduced
tumor cells at the site of tumor growth could elicit more6 Clinical and Developmental Immunology
Table 1: Clinical indications of IFNs. IFN-α with diﬀerent trade
names is the most indicated in the clinic. IFN-β is mostly indicated
for the treatment of relapsing remitting multiple sclerosis. IFN-γ is
only indicated for the chronic granulomatous disease. IFN-λ,t h e
new type of IFN, was tested for patients with chronic hepatitis C.
IFN type Indications in the clinic
IFN-α
Hairy cell leukemia
Multiple myeloma
Chronic myeloid leukemia
Follicular lymphoma
Cutaneous T lymphoma
Kaposi sarcoma
Melanoma
Renal cell carcinoma
Hepatocellular carcinoma
Condyloma accuminata
Hepatitis B
Hepatitis C
IFN-β Multiple sclerosis
IFN-γ Chronic granulomatous disease
IFN-λ Hepatitis C
eﬀective antitumor responses by acting directly on the tumor
microenvironment. Another advantage of the cytokine gene
transferintotumorcellsversussystemicadministrationisthe
potential of inducing the antitumor eﬀect without eliciting
the side eﬀects associated with the systemic administration
of high doses of cytokines.
To investigate the potential antitumoral role of IFN-
λ, we ﬁrst evaluated the response of B16 melanoma cells
to IFN-λ, by analyzing STAT1 activation and MHC class
I antigen expression. In comparison with IFN-α,w eh a v e
found that IFN-λ induces weak STAT1 phosphorylation
but strong stimulation of MHC class I antigen expression,
indicating a diﬀerence between IFN-α and IFN-λ in the
link intensity of cell signaling/biological activity. This result
warrants further investigation in comparing the response
to IFN-α and IFN-λ. By using gene transfer, we engineered
B16 cells, which constitutively produced mIFN-λ (B16.IFN-
λ cells). In response to their secretion of IFN-λ, B16.IFN-
λ cells exhibited constitutively high levels of MHC class I
antigen expression. All the C57BL/6 syngeneic mice injected
with parental B16 cells developed tumors. However, the con-
stitutive production of mIFN-λ by B16.IFN-λ cells markedly
aﬀected tumorigenicity of the cells. B16.IFN-λ cells were
either rejected by the host or grew at a slower rate than
control parental B16 cells. The antitumor eﬀect of IFN-λ was
dose dependent. B16.IFN-λ cells also inhibited the growth
of parental B16 cells when both cell types were injected
together [4]. We also used the engineered B16.IFN-λ Res.
cells, which, in addition to their constitutive IFN-λ secretion,
are completely resistant to IFN-λ, as demonstrated by the
lack of IFN-λ-induced MHC class I antigen expression.
Interestingly, similar to B16.IFN-λ cells, we have found a
reduction of the tumorigenicity of B16.IFN-λ Res. cells,
implying the involvement of host antitumor mechanisms
induced by IFN-λ [4].
Following our report on the characterization of the
mouse IFN-λ system and the potent antitumor activity of
IFN-λ in the B16 mouse melanoma model, independent
groups conﬁrmed the role of IFN-λ as an antitumoral agent
in melanoma and other tumor models. To demonstrate the
antitumor activity of IFN-λ, Sato et al. [68] used the
mouse melanoma B16F0 and B16F10 and the Colon26 cell
lines transfected with IFN-λ2 cDNA. The IFN-λ-transduced
B16F0 cells showed an increased activity of caspase 3/7,
an induction of p21 and a dephosphoryation of Rb, which
triggered a cell cycle arrest and apoptosis. These events,
obtained, in vitro, were apparently associated with a growth
delay, observed in vivo after the injection of the B16F0
transduced with IFN-λ. A delay in tumor growth was
also observed after the administration of the Colon26 cells
transduced with IFN-λ. By using the B16F10 cell line,
which represents metastatic mouse melanoma cells, the au-
thors showed that the overexpression of IFN-λ signiﬁcantly
inhibited lung metastasis. In another study, to evaluate
the antitumor activity of IFN-λ, Numasaki et al. [69]ﬁ r s t
transduced the mouse ﬁbrosarcoma cells, MCA2005, with
the retroviral vector PA317IL-28 (IFN-λ2). Following the
injection of the engineered tumor cells to mice, the authors
observed a signiﬁcant antitumor and antimetastatic eﬀect in
miceinoculatedwiththeMCA2005IL-28incomparisonwith
those injected with the parental tumor cells.
3.2. Investigation of the Antitumor Activities of IFN-λ in
the BNL Mouse Model of Hepatocellular Carcinoma (HCC).
HCC is the most prevalent type of liver cancer. It is the
ﬁfth most common solid tumor and the third leading
cause of cancer-related death worldwide. It is also the
second most lethal cancer with the ﬁve-year survival rate
below 9% [70–72]. Treatment options for HCC are limited
mainly because of the ineﬃciency of existing anticancer
chemotherapeutic drugs against HCC. Unfortunately, due to
a lack of biomarkers and screening for HCC, most patients
are diagnosed at advanced stages of the disease and do not
meet strict selection criteria for potentially curative surgical
tumor resection or orthotopic liver transplantation (OLT)
[73–75]. In patients with unresectable HCC and preserved
liver function, transarterial chemoembolization (TACE) has
been shown to prolong survival. However TACE is rarely
curative, and progression-free survival beyond 24 months is
not frequent [71, 76]. For patients with advanced disease,
systemic chemotherapy is of limited beneﬁt because of the
resistance of HCC to existing anticancer drugs and the fact
that about 50% of patients with HCC die secondary to liver
failure from cirrhosis [77, 78]. HCC occurs most frequently
in patients with cirrhosis as a result of chronic HBV
(hepatitis B virus) and HCV (hepatitis C virus) infections,
and alcohol abuse [72, 79]. Although the link between the
cancer and the viral infection is not fully understood yet,
there is some suggestion that viral infection interferes with
signal transduction and consequently disrupts the normal,
controlled growth of cells.Clinical and Developmental Immunology 7
Since IFN-α is used in the clinic for the treatment of
chronic HCV and HBV infections, several studies evaluated
the eﬀect of IFN treatment on the incidence of HCC [72].
It was previously shown that the systemic administration
of high doses and long-term IFN-α into nude mice bearing
human HCC with high metastatic potential, following
curativeresection,inhibitedtumormetastatisandrecurrence
[80]. The majority of clinical studies also concluded that IFN
therapy, alone or in combination with ribavirin, decreased
the incidence of HCC, particularly in patients with sustained
virological response [81–84]. Therefore, IFN alone or, per-
haps, in combination with other drugs can be used as a
preventivetherapyagainstthedevelopmentofHCCinHCV-
and HBV-infected patients. However, numerous side eﬀects
limit the overall tolerability of IFN-α, particularly in patients
with cirrhosis [85–87].
In the following part of this section, we describe our
ﬁndings on the antitumor properties of IFN-λ in the BNL
mouse model of HCC. To evaluate the antitumor activities
of both IFN-λ and IFN-α, we used a gene therapy approach
as previously described [4]. We expressed IFN-λ and IFN-
α genes under a strong constitutive promoter in BNL cells
and selected stable cell lines, BNL-IFN-λ and BNL-IFN-α,
constitutively expressing IFN-λ and IFN-α [45]. Since the
constitutive expression of IFN-λ at the tumor site was found
to aﬀect the tumorigenicity of B16 melanoma cells in vivo
[4], we examined whether similar eﬀects of IFN-λ would be
displayed in the case of BNL hepatoma. Mice injected with
BNL vector or parental BNL cells developed tumors in 4 to 6
weeks, whereas the tumor appearance for BNL-IFN-λ cells
was signiﬁcantly delayed. Similar eﬀects were obtained in
mice inoculated with BNL-IFN-α cells. These experiments
demonstrated that constitutive expression of IFNs at the
tumor site resulted in the delay of tumor growth in vivo.
Interestingly, we found that IFN-α and IFN-λ exhibited
similar antitumor activities [45].
4. PotentialAntitumor Mechanisms
of IFN-α andIFN-λ
4.1. Antitumor Mechanisms of IFN-α. Despite the antiprolif-
erative eﬀects of IFN-α, it seems that the direct eﬀects on
tumor cells may not be the major mechanism by which IFN-
α displays its antitumor activity. IFN-α can act indirectly
on the tumor by inhibiting angiogenesis which is induced
by the tumors and is required to promote their growth and
metastasis[88].Inmicebearinghumantumors,itwasclearly
demonstrated that the antitumor activity of IFN-α is asso-
ciated with the inhibition of tumor angiogenesis in bladder
carcinoma [89] and prostate cancer [90]. The involvement
of the immune system in the antitumor mechanism of IFN-
α was strongly suggested by Gresser et al. [91, 92]. Early
studies in tumor models have shown that an intact immune
system was essential in IFN-α-induced antitumor activities.
The inhibition of Friend leukemia cells (FLC) by IFN-α in
mice was shown to depend on the activation of host cells,
s u c ha sN Kc e l l sa n dm a c r o p h a g e s[ 92]. Both host humoral
and cellular immune mechanisms were involved in the
continued suppression of Friend erythroleukemia metastases
after IFN-α treatment in mice [91]. In addition, eﬀective
adaptiveimmunotherapywasobservedinaT-celllymphoma
model, after the injection of tumor-sensitized spleen cells
andIFN-α.Byusingantibodiesagainstdiﬀerentimmunecell
populations, it has been shown that CD4+ Tl y m p h o c y t e s
and CD8+ T lymphocytes were the major eﬀectors in the
antitumor activities induced by IFN-α [93, 94].
4.2. Antitumor Mechanisms of IFN-λ. Although IFN-α and
IFN-λ signal quite similarly (Figure 1), the mechanisms
underlying the antitumor activity of IFN-λ may be quali-
tatively diﬀerent from IFN-α.A sp r e v i o u s l yd e s c r i b e d ,w e
initially investigated whether type III IFNs also possessed
antitumor activities utilizing a gene therapy approach in
the B16 melanoma model. Since secreted IFN-λ did not
aﬀect the proliferation rate of B16 melanoma cells in vitro,
studies in the B16 melanoma model suggested that IFN-
λ acted through host mechanisms to elicit its antitumor
activity [4]. However, we did not observe a signiﬁcant long-
lasting immunity, implying that there may be a lack of
eﬀective adaptive immunity in the mice which rejected the
tumor. On the other hand, we noticed a reduction in tumor
vascularity in the presence of IFN-λ, suggesting a potential
role of IFN-λ in the tumor microenvironment [4]. Since
we found that keratinocytes are highly sensitive to IFN-λ
and they are known to interact with melanocytes, the cells
from which the melanoma originates, we suggested that
IFN-λ delivery to the tumor microenvironment may aﬀect
the function of the keratinocytes as well as other stroma
cells thereby promoting inhibition of tumor growth [4].
NK cells, the major eﬀectors of innate immunity, could
also be recruited to the tumor microenvironment and help
destroy the tumor cells. Two groups have reported that NK
cells played a role in the antitumor mechanisms of IFN-
λ. Sato et al. [68] have described the involvement of NK
cells in melanoma and colon cancer antitumor responses.
They have shown that transient transduction of B16 cells
with mouse IFN-λ cDNA enhanced MHC class I and Fas
expression, suppressed cell proliferation by inducing in-
creased caspase-3/7 activity, increased p21Waf1/Cip1 levels, and
dephosphorylated Rb (Ser780) in vitro [68]. This meant that
IFN-λ was able to induce cell cycle arrest and apoptotic
cell death in vitro. In addition, they have demonstrated
that overexpression of IFN-λ inhibited local and pulmonary
metastatic tumor formation in vivo. Depletion of NK cells,
by injecting an anti-asialo GM1 antibody before tumor cells
injection, revealed that NK cells are important in this IFN-
λ-mediated tumor growth inhibition in vivo, suggesting that
IFN-λ activated the innate immune response [68]. Numasaki
et al. [69] have also implicated NK cells, polymorphonuclear
neutrophils, and CD8+ T cells in the antitumoral activity
are induced by IFN-λ in the MCA205 murine ﬁbrosarcoma
mouse model. Inoculation of MCA205-IFN-λ cells into mice
enhanced IFN-γ production and cytotoxic T-cell activity in
the spleen. The antitumor activity of IFN-λ was partially
dependent on IFN-γ. In addition, IFN-λ increased the total
number of splenic NK cells in severe combined immun-
odeﬁciency (SCID) mice, enhanced IL-12-induced IFN-γ8 Clinical and Developmental Immunology
production in vivo, and expanded spleen cells in C57BL/6
mice. Furthermore, they reported that IL-12 augmented
the IFN-λ-mediated antitumor activity in the presence or
absenceofIFN-γ.Basedontheirﬁndings,theysuggestedthat
IFN-λ is able to induce both innate and adaptive immune
responses to suppress in vivo tumor growth [69].
Our recent study in the BNL hepatoma model also
revealedthatNKcellsareimplicatedintheantitumoractivity
induced by IFN-λ and probably more potently than IFN-
α.H o w e v e r ,i nc o n t r a s tt oI F N - α, we did not detect any
response after in vitro treatment of NK cells by IFN-λ,
suggesting that IFN-λ may activate other cells, which then
mediate NK cell activation [45]. There was also a marked
NK cell inﬁltration in IFN-λ-producing tumors. In addition,
IFN-λ and, to a lesser extent, IFN-α enhanced immunocy-
totoxicity of splenocytes primed with irradiated BNL cells.
Splenocyte cytotoxicity against BNL cells was dependent on
IL-12 and IFN-γ and mediated by dendritic cells. In contrast
to NK cells, isolated from spleen, CD11c+ and mPDCA+
dendritic cells responded directly to IFN-λ, suggesting that
the eﬀects of IFN-λ on NK cells are mediated by other
IFN-λ-responsive cells, such as DCs [45]. On the other
hand, a signiﬁcant decrease in CD4+CD25+Foxp3+ Tregs
was observed in mice inoculated with BNL cells secreting
IFN-α, whereas the moderate decrease in Tregs observed in
mice receiving BNL cells secreting IFN-λ was not statistically
signiﬁcant [45]. Therefore, antitumor mechanisms activated
by IFN-α and IFN-λ may diﬀer; IFN-λ increased the number
of NK cells at the tumor site whereas IFN-α had a stronger
eﬀect on Tregs in the BNL model.
These studies altogether suggest that although IFN-α and
IFN-λ signal quite similarly, diﬀerences exist in their biolog-
ical potency, kinetics, and the sets of target cells sensitive to
IFN-λ and IFN-α. Therefore, these two types of IFNs may
have distinct physiological functions.
5. IFN-λand IFN-α:AlliesinAchieving
Higher Antitumor Activities?
Unlike IFN-α, only a small subset of cells are sensitive to
IFN-λ, implying that its potential clinical use may be
associated with limited side eﬀects. This presumption raises
the question whether IFN-λ could be an alternative to IFN-α
in cancer therapy. However, despite the severe and numerous
side eﬀects inherent to IFN-α treatment [65], we believe
that alternative treatment to IFN-α should be weighed ﬁrst
against the real beneﬁts to patients in terms of overall
survival and their tumor clearance. We have demonstrated
in the BNL hepatoma model that the combination of IFN-
λ and IFN-α could achieve a marked antitumor activity in
comparisonwiththeuseofeachIFNalone[62].Thebeneﬁts
of the combination therapy of IFN-λ and IFN-α have been
demonstrated both by using a gene therapy approach and by
directadministrationofIFNstothemicebearingthetumors.
The mice injected with BNL cells secreting both IFN-λ and
IFN-α can completely reject the tumor, in contrast to the
mice that only received the BNL-IFN-λ cells or the BNL-
IFN-α cells. Furthermore, mice bearing established tumors
and treated with exogenous IFN-λ and IFN-α showed a
drastic tumor repression. This eﬀect was observed when
the IFNs were delivered locally and even at low doses.
Therefore, we believe that IFN-λ is not simply acting like
IFN-α, with reduced side eﬀects, but can be combined with
IFN-α to achieve eﬃcient antitumor activity. Combination
of IFN-λ with low doses of IFN-α, which are subtherapeutic
but less toxic [67], may improve IFN therapy and beneﬁt
cancer patients. Combinational therapy of IFN-λ and IFN-
α may achieve ultimate antitumor activity by inducing com-
plementary mechanisms directly on the tumor cells or by
indirectly modulating the tumor microenvironment, thereby
leading to the stimulation of the immune response against
the tumor and the inhibition of tumor angiogenesis. By
acting with diﬀerent intensities on the same targets, IFN-λ
and IFN-α may generate a high level of synergy, leading to a
potent antitumor activity.
6. Conclusions
Similarly to IFN-α,I F N - λ has been shown to play an im-
portant role in cancer and viral disease treatment. Although
the two IFNs act through an identical signaling pathway in
the cell, the pattern of their activity seems to be diﬀerent
in vivo, implying that IFN-λ and IFN-α are not redundant
cytokines. By acting on some targets with diﬀerent inten-
sities, we believe that IFN-λ and IFN-α act in concert to
better control tumor development in vivo. Therefore, to
achieve better treatments for viral diseases or cancers, we
believethatthedevelopmentofacombinationtherapyrather
than the use of each IFN alone will be more beneﬁcial
for the patients. The combination of IFNs with other cy-
tokines, growth factors, or their antagonists could also be an
important strategy for the improvement of the IFN therapy.
Transforming growth factor-beta (TGFβ)w h i c hp l a y sa
dual role in cancer, mediating tumor-suppresive activities
at early stages and prooncogenic activities at later stages of
tumor progression [95, 96], could represent one potentially
important modulator or mediator of the IFN response.
Understanding the potential crosstalks between IFN-α,I F N -
λ and other cytokines or growth factors, such as TGFβ,c o u l d
be rewarding and lead to new preclinical studies in animal
models and new clinical trials resulting in better cancer
treatments.
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